Total Valuation
PharmaCyte Biotech has a market cap or net worth of $4.41M. The enterprise value is -$14.82M.
Market Cap$4.41M
Enterprise Value-$14.82M
Share Statistics
PharmaCyte Biotech has 10,735,649 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding10,735,649
Owned by Insiders6.93%
Owned by Institutions0.21%
Financial Efficiency
PharmaCyte Biotech’s return on equity (ROE) is -0.58 and return on invested capital (ROIC) is -14.92%.
Return on Equity (ROE)-0.58
Return on Assets (ROA)-0.42
Return on Invested Capital (ROIC)-14.92%
Return on Capital Employed (ROCE)-0.15
Revenue Per Employee0.00
Profits Per Employee-9.71M
Employee Count2
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of PharmaCyte Biotech is ―. PharmaCyte Biotech’s PEG ratio is 0.00140.
PE Ratio―
PS Ratio0.00
PB Ratio0.15
Price to Fair Value0.15
Price to FCF-0.98
Price to Operating Cash Flow-1.10
PEG Ratio0.00140
Income Statement
In the last 12 months, PharmaCyte Biotech had revenue of 0.00 and earned -19.42M in profits. Earnings per share was -2.77.
Revenue0.00
Gross Profit0.00
Operating Income-6.85M
Pretax Income-19.42M
Net Income-19.42M
EBITDA-5.30M
Earnings Per Share (EPS)-2.77
Cash Flow
In the last 12 months, operating cash flow was -3.94M and capital expenditures 0.00, giving a free cash flow of -3.94M billion.
Operating Cash Flow-3.94M
Free Cash Flow-3.94M
Free Cash Flow per Share-0.37
Dividends & Yields
PharmaCyte Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.80
52-Week Price Change-60.10%
50-Day Moving Average0.51
200-Day Moving Average0.69
Relative Strength Index (RSI)35.84
Average Volume (3m)292.06K
Important Dates
PharmaCyte Biotech upcoming earnings date is Mar 16, 2022, Before Open (Confirmed).
Last Earnings DateDec 15, 2021
Next Earnings DateMar 16, 2022
Ex-Dividend Date―
Financial Position
PharmaCyte Biotech as a current ratio of 45.28, with Debt / Equity ratio of 0.00%
Current Ratio45.28
Quick Ratio45.28
Debt to Market Cap0.00
Net Debt to EBITDA3.51
Interest Coverage Ratio0.00
Taxes
In the past 12 months, PharmaCyte Biotech has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
PharmaCyte Biotech EV to EBITDA ratio is 2.55, with an EV/FCF ratio of 2.63.
EV to Sales0.00
EV to EBITDA2.55
EV to Free Cash Flow2.63
EV to Operating Cash Flow2.63
Balance Sheet
PharmaCyte Biotech has $30.51M in cash and marketable securities with $0.00 in debt, giving a net cash position of $30.51M billion.
Cash & Marketable Securities$30.51M
Total Debt$0.00
Net Cash$30.51M
Net Cash Per Share$2.84
Tangible Book Value Per Share$4.99
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for PharmaCyte Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-422.63%